Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes

Mise à jour : Il y a 4 ans
Référence : NCT01127269

Femme et Homme

  • | Pays :
  • Argentina
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary Objective: Percentage of patients achieving Glycosylated Hemoglobin (HbA1c) < 7% with no severe or nocturnal hypoglycemic episodes at 6 months Secondary Objectives: - Glycosylated Hemoglobin (HbA1c) change from baseline to 6 months - Insulin glargine dose at 3 and 6 months - Hypoglycemic episodes (all types)


Critère d'inclusion

  • Diabetes Mellitus, Type 2

Liens